Unknown

Dataset Information

0

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.


ABSTRACT: PURPOSE: Alkylphosphocholines represent a new class of cytostatic drugs with a novel mode of action. Erufosine (ErPC3), the first compound of this class that can be administered intravenously, has recently been shown to be active against human tumor and leukemic cell lines. METHODS: In order to evaluate the antileukemic potential of ErPC3 in acute myeloid leukemia (AML) the lethal concentration 50% (LC 50) was determined using WST-1 assay. For analysis of cell death, staining for Annexin V and activated caspase 3 was performed. An interaction analysis was performed by calculation of combination index and construction of isobolograms. RESULTS: The LC 50 was 7.4 microg/ml after 24 h and 3.2 microg/ml after 72 h in HL 60 cells and 30.1 and 8.6 microg/ml, respectively, in 19 fresh samples from patients with AML. ErPC3 was found to be cytotoxic in HL60 cells with distinct activation of caspase 3. ErPC3 was not cross-resistant with cytarabine, idarubicine and etoposide as shown by the linear relation of respective LC 50s. The latter agents, however, exerted an additive cytotoxicity in combination with ErPC3 as revealed by isobologram analysis and combination index, although results are uneven for idarubicine. CONCLUSION: Based on these data ErPC3 appears as a novel antileukemic candidate drug, which needs to be explored further in the treatment of AML.

SUBMITTER: Fiegl M 

PROVIDER: S-EPMC2755757 | BioStudies | 2008-01-01

SECONDARY ACCESSION(S): 10.1007/s00280-007-0612-7

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3432483 | BioStudies
2017-03-15 | GSE96599 | GEO
2016-01-01 | S-EPMC4918815 | BioStudies
2021-01-01 | S-EPMC7957697 | BioStudies
2010-01-01 | S-EPMC2840060 | BioStudies
1000-01-01 | S-EPMC5296912 | BioStudies
2020-01-01 | S-EPMC7076174 | BioStudies
2019-01-01 | S-EPMC6935253 | BioStudies
2015-01-01 | S-EPMC4305021 | BioStudies
2003-01-01 | S-EPMC2394409 | BioStudies